Regulatory Press Releases

Regulatory information that Orexo is obliged to make public pursuant to the EU Market Abuse Regulation, Securities Market Act and the Financial Instruments Trading Act.

Regulatory
Pressrelease

Orexo has successfully completed its private placement of approx. SEK 346.5m

29 August 2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF OREXO.
Regulatory
Pressrelease

Orexo intends to conduct a private placement of shares to Swedish and international institutional and strategic investors

28 August 2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF OREXO.
Regulatory
Pressrelease

Notice of Annual General Meeting of Orexo

14 March 2014
The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Tuesday 15 April 2014, at 4.00 pm in Orexo’s facilities at Virdings allé 32A, in Uppsala, Sweden.
Regulatory
Interim Report

Interim report January-June 2013

12 July 2013
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2012. FDA approves Zubsolv™ for maintenance treatment of opioid dependence
Regulatory
Pressrelease

Notice of Annual General Meeting of Orexo

12 March 2013
The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Thursday 11 April 2013, at 5.00 pm in Orexo’s facilities at Virdings allé 32A, in Uppsala, Sweden.
Regulatory
Pressrelease

Orexo provides US commercialization progress update and direction for 2013 financial outlook

19 December 2012
Orexo AB (Orexo) today informs about the progress towards becoming a full-fledged specialty pharmaceutical company with a US commercial presence.  Orexo also announced the company project it will turn profitable in late 2013, with the current assumptions on regulatory timing and launch of Zubsolv™ in September 2013. Zubsolv™ and Abstral® to be commercialized in partnership
Regulatory
Pressrelease

Orexo reports successful achievement of product stability data for OX219 – submission of the US file now advanced 5 months to September 2012

21 August 2012
Swedish specialty pharmaceutical company Orexo today communicated that it projects a late Q3 regulatory submission to the US regulatory agency FDA of its treatment of opioid dependence, OX219. Opioid dependence is in the US increasingly being recognized as a major health problem, with over two million Americans affected and costing the society an estimated USD 25 billion in related health care cost.
Regulatory
Pressrelease

Notice of Extraordinary General Meeting of Orexo

14 June 2012
The shareholders in Orexo AB (publ) are summoned to the extraordinary general meeting, to be held on Friday 13 July 2012, at 3.00 pm in Orexos facilities at Virdings allé 32A, in Uppsala, Sweden.
Regulatory
Pressrelease

Notice of Annual General Meeting of Orexo

12 March 2012
The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Wednesday 11 April 2012, at 4.00 pm in Orexos facilities at Virdings allé 32A, in Uppsala, Sweden.
Regulatory
Pressrelease

Orexo and Uppsala University receive Swedish Research Council grant for bioceramics project

30 November 2011
Uppsala, November 30 2011 - Orexo AB (STO: ORX) has been awarded a 2.1 million SEK grant from the Swedish Research Council for the project "Bioceramic materials for slow release of potent drugs". The project will be conducted between 2012 and 2015 in collaboration with a research team, led by Professor Håkan Engqvist, Applied Materials Science, Department of Engineering Sciences at Uppsala University.
Regulatory
Interim Report

Interim report January-June 2011

10 August 2011
STRONG SALES INCREASE FOR ABSTRAL® References made in this interim report relate to the Group unless otherwise stated. Figures in parentheses relate to the corresponding period in 2010.
Regulatory
Pressrelease

Orexo takes leading position in diagnostic breath tests through acquisition

14 July 2011
Uppsala, July 14, 2011 – Orexo AB (STO: ORX) has, through its subsidiary Kibion AB, acquired the German company Wagner Analysen Technik GmbH (WAT). WAT is a leading manufacturer of IRIS instruments and substrates for diagnostic breath tests. The acquisition turns Kibion into a complete solutions provider of both diagnostic breath tests and instruments, with a leading position in Helicobacter pylori tests.
Regulatory
Pressrelease

Abstral® launches in Canada

14 June 2011
Uppsala, Sweden, June 14 2011 – Through its local partner, Orexo now initiates marketing and sales of the pain treatment Abstral in Canada.
Regulatory
Interim Report

Interim report, January-March 2011

4 May 2011
References made in this interim report relate to the Group unless otherwise stated. Figures in parentheses relate to the same period in the previous year.
Regulatory
Pressrelease

Notice of Annual General Meeting of Orexo

8 March 2011
The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Thursday 7 April 2011, at 3.00 pm at IVA’s Konferenscenter, Grev Turegatan 16, in Stockholm, Sweden.
Regulatory
Annual Financial Statement

Orexo AB (publ.) - Year-end Report, January to December 2010

16 February 2011
Uppsala, February 16, 2011 - Abstral continues to grow strongly and is now also approved in the USA. OX-MPI has made significant progress towards clinical trials and has received its first milestone payment. The three new programs OX219, OX51 and OX27 announced in August 2010 have now all entered the clinical phase.
Regulatory
Pressrelease

Anders Lundström to be the new CEO of Orexo

13 January 2011
Uppsala, January 13, 2011 - Orexo AB (STO: ORX) announces today that Anders Lundström has been appointed as its new CEO, to lead the company through its commercial development. He comes from Biogen Idec in the US, one of the world’s most successful biotech companies.
Regulatory
Pressrelease

Notice of Annual General Meeting in Orexo AB

23 March 2010
The shareholders in Orexo AB (publ) are summoned to the annual general meeting (the “Meeting”), to be held on Wednesday 21 April 2010, at 3.00 pm at IVA’s Konferenscenter, Grev Turegatan 16, in Stockholm, Sweden.
Regulatory
Pressrelease

Notice of Extraordinary General Meeting

15 March 2010
The shareholders in Orexo AB (publ) are summoned to an extraordinary general meeting to be held on Wednesday 31 March 2010, at 10.00 am at IVA’s Konferenscenter, Grev Turegatan 16, in Stockholm, Sweden.
Regulatory
Pressrelease

UK Marketing Approval Issued for Abstral

23 September 2008
Orexo AB (OMX: ORX) confirms the announcement made by ProStrakan Group plc (LSE: PSK), Orexo's partner for Abstral® in Europe and North America, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Marketing Authorisation for Abstral (for breakthrough cancer pain). As a result of the approval, Orexo will receive a milestone payment of USD 1 million.
Regulatory
Pressrelease

Orexo and Boehringer Ingelheim extend their research collaboration

8 September 2008
Uppsala, Sweden, September 8, 2008 – Orexo AB (OMX: ORX), the Swedish pharmaceutical company and Boehringer Ingelheim, the international pharmaceutical company headquartered in Ingelheim, Germany, have extended their existing three year research collaboration for a further 12 months from November 2008. The research collaboration is a part of an exclusive world-wide license to develop and market a new class of drugs with a novel mechanism of action for the treatment of pain and inflammation.
Regulatory
Pressrelease

Orexo initiates clinical phase II program for OX914 - a new product candidate for the treatment of inflammatory airway diseases

2 September 2008
Uppsala, Sweden, September 2, 2008 – Orexo AB (OMX: ORX), the Swedish pharmaceutical company, announced today that the phase II program for the product OX914 has started. This is a new product candidate for the treatment of inflammatory airway diseases including asthma, COPD (chronic obstructive pulmonary disease) and rhinitis.
Regulatory
Pressrelease

Orexo and ProStrakan Extend Licensing Agreement for Rapinyl/Abstral and change Partner in North America

31 July 2008
Uppsala, Sweden, 31 July, 2008 – Orexo AB (OMX: ORX), the Swedish pharmaceutical company, and ProStrakan Group plc, the Scottish-based international specialty pharmaceutical company, have extended their existing European licensing agreement for Rapinyl™ (Abstral®), for breakthrough cancer pain, to include North America. This change of partner in North America follows the decision made by Endo Pharmaceuticals Holdings Inc. today following its own internal strategy changes to return all rights for Rapinyl™ (Abstral®) to Orexo. Endo has invested approximately $40 million in the development of Rapinyl™, and Orexo has received an additional $26.9 million in licensing payments. Endo will finalize and finance the current phase III studies of Rapinyl™ expected to end in December 2008.
Regulatory
Pressrelease

The FDA has accepted for filing the registration application for Sublinox™

29 July 2008
The submitted registration application for SublinoxTM (OX22) has been accepted by the FDA as complete for substantive review after initial evaluation. SublinoxTM contains the well-known active substance zolpidem and is based on Orexo’s sublingual technology, involving a rapidly disintegrating tablet placed under the tongue.
Regulatory
Pressrelease

Orexo report Abstral (Rapinyl) approval in Europe

26 June 2008
Uppsala, Sweden, 26 June, 2008 – Orexo AB (OMX: ORX), the Swedish pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Rapinyl, for breakthrough cancer pain. ProStrakan Group plc, the international speciality pharmaceutical is Orexo´s exclusive partner for sales and marketing of Abstral/Rapinyl in Europe. Abstral/Rapinyl will be launched in Sweden in Q3 2008 and, as a result of today’s announcement, across Europe from the end of 2008 under the brand name Abstral.
Regulatory
Pressrelease

Orexo strengthens the Executive Management Group

9 June 2008
Orexo recruits Robin Wright, with extensive experience from international corporate finance and business development in the pharmaceutical and life science sector, as responsible for Business & Commercial Development. Robin Wright will be part of Orexo’s Executive Management Group.
Regulatory
Pressrelease

Orexo reports positive results from phase I study for OX19

29 April 2008
Data from a phase I study confirms that Orexo’s new nasal spray formula for the administration of the desmopressin peptide for incontinence, shows significantly better uptake than nasal sprays currently on the market. Next step for Orexo is to seek partnership for further development of the product.
Regulatory
Pressrelease

Orexo announces results confirming the clinical profile of OX17 in reflux disease (GERD)

27 March 2008
New clinical data from a phase II study confirms the competitive profile of Orexo’s product OX17 in GERD patients, i.e. fast, effective and sustained inhibition of gastric acid production, a prerequisite for effective symptom relief in the patient. The result demonstrates the clinical potential of OX17 and is an important step in the development of a competitive product.
Regulatory
Pressrelease

Rapinyl™ has received Swedish Marketing Authorization

7 March 2008
Uppsala, Sweden, 7th March 2008 - Orexo´s licensing partner for Rapinyl™ in Europe, ProStrakan Group plc announces that Rapinyl™ has received Swedish Marketing Authorization. It is anticipated that the product branded as “Abstral” will be launched in Sweden in Q3 2008 through Orexo´s joint venture with ProStrakan, which operates in the Nordic countries.
Regulatory
Pressrelease

Orexo discloses new mechanism for asthma and COPD treatment

10 January 2008
The discovery of the eoxins and their characteristics has paved the way for a new class of pharmaceuticals for treatment of asthma and COPD. One of the world's most-cited scientific journals, Proceedings of the National Academy of Sciences of the United States (PNAS), is now publishing Orexo’s research on the initial discovery and biological functions of eoxins. The publication describes the scientific rationale behind Orexo’s drug development program on eoxin inhibitors.
Regulatory
Pressrelease

Orexo announces new Executive Management Team

26 November 2007
Following the completion of the Biolipox acquisition, Orexo has appointed a new Executive Management Team. The new Executive Management Team consists of Torbjörn Bjerke (President & CEO), Claes Wenthzel (Executive Vice President & CFO), Thomas Lundqvist (Executive Vice President och Executive Advisor), Göran Smedegård (Vice President Business Development & Commercial Development) and Göran Tornling (Executive Vice President R&D).
Regulatory
Pressrelease

The board of directors of Orexo resolves to issue new shares with payment in kind

21 November 2007
Due to Orexo AB’s acquisition of Biolipox AB, the board of directors of Orexo has today resolved, in accordance with the authorization from the extraordinary shareholders’ meeting held on November 13, 2007, to issue not more than 7,630,895 new shares and not more than 926,000 warrants entitling to subscription for not more than 926,000 new shares in Orexo, whereby the company’s share capital may be increased by not more than SEK 3,422,758.
Regulatory
Pressrelease

Orexo acquires Biolipox – Update regarding revised transaction structure and proposal regarding election of chairman and members of the board of directors for the Extraordinary General Meeting on November 13, 2007

12 November 2007
As previously announced in a press release on October 15, 2007, Orexo AB (OMX Nordic List, Mid Cap: ORX) and the principal owners of Biolipox AB have reached an agreement according to which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Regulatory
Pressrelease

Orexo to acquire Biolipox - Update

26 October 2007
As previously announced in a press release on October 15, 2007 Orexo AB (OMX Nordic List, Mid Cap: ORX) and the principal owners of Biolipox AB have reached an agreement under which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Regulatory
Pressrelease

Orexo signs distribution agreement with Hospira in Asia for pain product Rapinyl™

25 October 2007
Orexo AB and the specialty pharmaceuticals and medication delivery company Hospira have signed a distribution agreement that grants Hospira exclusive rights to market and sell Rapinyl™, Orexo’s patented product for treatment of break-through pain in cancer, in Asia Pacific markets including Australia and New Zealand. Market rights for the US, the EU and Japan were previously out-licensed, while another distribution agreement has also been signed for the CIS, Bulgaria and Romania.
Regulatory
Pressrelease

Orexo to acquire Biolipox - building a specialty pharma company driven by innovation

15 October 2007
Orexo AB (OMX Nordic List, Mid Cap: ORX) and the principal owners of Biolipox AB have reached an agreement under which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The acquisition will create an innovative specialty pharma company with a broad product pipeline, global partnerships with major financial potential, and established sales channels. Substantial shareholder value will be created through operational synergies and by optimizing the potential of the combined product pipeline. The transaction will take place through an issue in kind to Biolipox's shareholders. The deal values Biolipox at SEK 856 million, and payment will be made through an issue of a maximum of 8,560,000 Orexo shares. The final structure of the transaction is dependent on Orexo's completion of due diligence of Biolipox. The deal is also conditional upon approval of the issue in kind by an extraordinary general meeting of Orexo and customary regulatory approvals. A press conference will be held jointly by Orexo and Biolipox at 10 a.m. today, Monday, 15 October 2007. Location: Summit, Grev Turegatan 30, Stockholm.
Regulatory
Pressrelease

Orexo shows positive results in completed comparative Phase III profile study of the Sublinox™ sleep aid involving insomnia patients

1 October 2007
Orexo has completed a pharmocological profile study for Sublinox™ (OX22) – for treatment of temporary sleeping disturbances. The study shows that Sublinox™ (OX22) acts 30 percent faster than Ambien® as a sleep aid for patients suffering from sleep disturbances. The study also shows that patients remain asleep throughout the night and strengthens existing documentation that Sublinox™ (OX22) represents a safe and effective treatment for temporary insomnia.
Regulatory
Pressrelease

Orexo’s Rapinyl™ nearing regulatory decision in Europe

28 September 2007
Orexo´s European licensing partner ProStrakan Group plc, for the cancer breakthrough pain product Rapinyl™ on the European market, today announced that Rapinyl™ will be referred for review by the Committee for Medicinal Products for Human Use (CHMP) of the EMEA. Of the 25 member states involved in the EU Decentralised Procedure (DCP) for Rapinyl™, 21 consider this product to be approvable.
Regulatory
Pressrelease

Orexo´s treatment for incontinence/nocturia entering Phase I

29 August 2007
FOR MEDIA INFORMATION Simon Vane Percy / Sarah Roberts Vane Percy & Roberts (T) +44 (0)1737 821891 / 892 (F) +44 (0)1737 821899 (e) simon@vanepercy.com / sarah@vanepercy.com Orexo’s product for nocturia and on demand treatment of urinary incontinence, OX 19 (sublingual desmopressin) has started phase 1 trials. Orexo has developed several formulations and is now proceeding to investigate the lead formulation. The bioavailability trial, which is taking place in Sweden, is expected to be completed by the end of this year. OX 19 exploits Orexo’s novel sublingual tablet technology which enables rapid and reliable onset of action.
Regulatory
Pressrelease

Orexo strengthens its clinical and regulatory team with the appointment of three senior executives

17 August 2007
FOR MEDIA INFORMATION Simon Vane Percy / Sarah Roberts Vane Percy & Roberts (T) 01737 821891 / 892 (F) 01737 821899 (e) simon@vanepercy.com / sarah@vanepercy.com Orexo (OMX Midcap:ORX.) has strengthened its clinical and regulatory team with the appointment of three senior executives - Mats Eriksson PhD, VP Research and Clinical Development and Medical Director for Orexo, Christina Ståhl MSc. Pharm, Vice President Regulatory Affairs, and Anne Marie Ciupitu MSc, PhD, Director QA/QC.
Regulatory
Pressrelease

Orexo establishes sales force in Nordic markets, by entering into a joint venture with ProStrakan

1 August 2007
FOR MEDIA INFORMATION Simon Vane Percy / Sarah Roberts Vane Percy & Roberts (T) 01737 821891 / 892 (F) 01737 821899 (e) simon@vanepercy.com / sarah@vanepercy.com Orexo (OMX Midcap:ORX.) has embarked on the next phase of its growth strategy by entering into a joint venture agreement with ProStrakan in the Nordic territories. Together Orexo and ProStrakan are establishing a sales operation, which will be owned equally. The new entity will have Nordic sales rights for both Orexo’s and ProStrakan’s portfolio which will include currently marketed and future products, Tostrex®, Rectogesic® and Droperidol®, followed by Rapinyl™, Orexo’s patented product for the treatment of cancer break through pain for which ProStrakan holds the European distribution rights, and ProStrakan’s product Sancuso® for the prevention of chemotherapy-induced nausea and vomiting, both currently undergoing the European regulatory process.
Regulatory
Pressrelease

Orexo receives European patent approval for OX 17

9 May 2007
Orexo has been informed by the European patent authority that Orexo’s patent for the combination concept for the treatment of GERD – gastroesophageal reflux disease – has been granted and will be published on May 30, 2007. The patent is a formulation patent protecting combinations of H2-receptor blockers and proton pump inhibitors (PPI). The patent has previously been approved in China, Australia and New Zealand, and patent is pending in the North-American market.
Regulatory
Pressrelease

Orexo submits registration application (IND) to FDA to complete the Phase III clinical study for the insomnia product Sublinox™ (OX 22)

20 December 2006
Orexo AB has submitted a registration application to FDA to complete Orexo’s clinical Phase III program for the insomnia product Sublinox™ (OX 22) - Orexo´s patented product for treatment of temporary sleeping disturbances. The studies are expected to be completed in the second half of 2007. A registration application for the US and EU markets are estimated to be submitted at the end of 2007.
Regulatory
Pressrelease

Orexo announces another agreement for its pain product Rapinyl™

19 December 2006
Orexo AB and the Hungarian pharmaceutical company Gedeon Richter Ltd. today announced that they have entered into a distribution agreement under which Gedeon Richter receives exclusive rights to market and sell Rapinyl™ – Orexo´s patented product for management of breakthrough cancer pain – in CIS, Bulgaria and Rumania. This is Orexo’s first distribution agreement for Rapinyl™. The marketing rights have previously been out-licensed in the U.S, EU and Japan.
Regulatory
Pressrelease

Orexo strengthens its organization for continued and expanded development of its portfolio – Christina Rångemark Åkerman appointed Head of Technology- and Product Development

5 December 2006
Orexo AB has appointed Christina Rångemark Åkerman as Senior Vice President and Head of Technology and Product Development. She assumes her position on February 1, 2007. She will be responsible for project management, R&D, clinical development and regulatory affairs. The recruitment is a step to further strengthen Orexo’s organization as the company prepares for increasing its investments in developing new products, and simultaneously, preparing some of its existing products for entering clinical phase III-trials.
Regulatory
Pressrelease

Nomination Committee for Orexo´s Annual General Meeting 2007

9 November 2006
At Orexo AB;s Annual General Meeting on 27 April 2006, it was resolved that the Chairman of the Board of Directors shall, not later than six months before the Annual General Meeting, announce a Nomination Committee comprising one representative for each of the three largest shareholders in terms of the number of votes.
Regulatory
Pressrelease

Orexo builds a platform for new, innovative drugs by developing a unique drug delivery technology

24 October 2006
The pharmaceutical company Orexo has initiated a collaboration with the medical technology company Doxa. Orexo and Doxa are to develop new, innovative pharmaceuticals based on a unique drug delivery technology, which will be designed for slow and controlled release of the active ingredient. The initial and primary objective is to develop a new, improved pharmaceutical product for pain treatment.
Regulatory
Pressrelease

Orexo receives SEK 38 M from Endo Pharmaceuticals Inc.

23 October 2006
Orexo AB is receiving license revenue amounting to USD 5.2 M (slightly more than SEK 38 M) from Endo Pharmaceuticals Inc. pertaining to Rapinyl™. Endo Pharmaceuticals has exclusive rights to the further development and marketing of Rapinyl™ on the North American market and is currently conducting a Phase III program to support registration in the US for treatment of breakthrough pain in opiod-tolerant cancer patients. To date, Orexo has received license revenues from Endo Pharmaceuticals Inc. totaling about SEK 161 M.
Regulatory
Pressrelease

Development milestone payment to Orexo after completed clinical study

3 October 2005
Orexo AB has met the requirements for its first $6.5 million development milestone payment from Endo Pharmaceuticals Inc., following the completion of a clinical trial of Rapinyl™ (OX 20) with positive outcome. In this trial, the dose range to be used in the next stage of development was established. Orexo’s patented product Rapinyl™ (OX 20) is being studied for the management of breakthrough cancer pain . The two companies entered into a licensing agreement August 2004, which gives Endo Pharmaceuticals exclusive rights to develop and market Rapinyl™ (OX 20) for the North American market.
Regulatory
Pressrelease

Orexo recruits and reorganizes for continued rapid expansion

26 August 2005
Claes Wenthzel has been appointed Executive Vice President and Chief Financial Officer (CFO) at Orexo AB, with overall responsibility for the company’s financial and administrative functions. Thomas Lundqvist, co-founder of Orexo, moves from his role as Executive Vice President and Head of Research & Development to become Executive Vice President & Chief Scientific Officer (CSO), with overall responsibility for the company’s scientific operations. Concurrently, Nils-Otto Ahnfelt, formerly Project Director, assumes the position Vice President Research & Development.
Regulatory
Pressrelease

Professor John Sjögren new board member of Orexo AB

4 May 2005
At Orexo’s Annual General Meeting on April 20, 2005, Professor John Sjögren was elected new member of the Board of Directors. John Sjögren has many years of experience in drug development within Astra Hässle and unique knowledge in pharmaceutics – the science of the delivery of pharmaceutical substances for the most effective therapeutic impact.
Regulatory
Pressrelease

Orexo completes clinical study with positive results

28 February 2005
Orexo has completed an efficacy study for OX 22, with positive results. OX 22 is a pharmaceutical product for the treatment of temporary insomnia, a product which is considered to have substantial medical and commercial potential. Negotiation with potential partners for commercialisation of OX 22 has been initiated.
Regulatory
Pressrelease

Orexo accelerates its portfolio development – Dr. Nils-Otto Ahnfelt assumes position as Project Director

28 January 2005
Uppsala-based biotechnology company Orexo is further strengthening its organization through the recruitment of Dr. Nils-Otto Ahnfelt as Project Director, with the task of driving development of the company’s product portfolio on a project basis. Dr. Ahnfelt will also be a member of Orexo’s executive management team. Nils-Otto Ahnfelt has more than 20 years of industry experience, mainly from Pharmacia, and joins Orexo from Doxa AB, where he was head of the company’s Research and Development .
Regulatory
Pressrelease

Orexo expands further – broadens operations and recruits new employees

13 January 2005
Sweden-based biotechnology company Orexo, continues to expand. During the first half of 2005, a new, directly owned analytical laboratory will become operational, strengthening the company’s ability to accelerate the development of its´ product portfolio. Furthermore, additional expertise has been recruited to facilitate this development.
Regulatory
Pressrelease

Monica Caneman new board member of Orexo AB

26 July 2004
Orexo AB in Uppsala announces the election of Monica Caneman as new member of its Board of Directors. Monica Caneman previously worked for SEB, where she was employed for more than 20 years, the last four as Deputy CEO.